Jennifer Michaelson
Chief Tech/Sci/R&D Officer bei CULLINAN THERAPEUTICS, INC.
Vermögen: 2 Mio $ am 31.03.2024
Profil
Jennifer Michaelson is currently the Chief Scientific Officer at Cullinan Oncology, Inc. She previously worked as the Director-Tumor Immunology at Jounce Therapeutics, Inc. and as the Chief Development Officer-Biologics at Cullinan Oncology LLC from 2020 to 2022.
Additionally, she served as the Head-Biologics at Celsius Therapeutics, Inc. in 2017.
Dr. Michaelson completed her undergraduate degree at Princeton University and obtained a doctorate from Albert Einstein College of Medicine, Inc.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 22.02.2024 | 137 582 ( 0,32% ) | 2 Mio $ | 31.03.2024 |
Aktive Positionen von Jennifer Michaelson
| Unternehmen | Position | Beginn |
|---|---|---|
| CULLINAN THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 01.06.2023 |
Ehemalige bekannte Positionen von Jennifer Michaelson
| Unternehmen | Position | Ende |
|---|---|---|
Celsius Therapeutics, Inc.
 Celsius Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Celsius Therapeutics, Inc. translates single-cell genomic insights into precision therapeutics for autoimmune diseases and cancer. The company was founded by Jeffrey A. Bluestone, Vijay K. Kuchroo, Christoph S. Lengauer, Aviv Regev and Ramnik Xavier in 2018 and is headquartered in Boston, MA. | Corporate Officer/Principal | 01.12.2017 |
| JOUNCE THERAPEUTICS, INC. | Corporate Officer/Principal | 01.07.2017 |
Cullinan Oncology LLC
 Cullinan Oncology LLC Financial ConglomeratesFinance Cullinan Oncology LLC is a biopharmaceutical company, which engages in the development of a pipeline of targeted oncology and immuno-oncology therapies for cancer diseases. The company was founded by Patrick Baeuerle on September 15, 2016 and is headquartered in Cambridge, MA. | Corporate Officer/Principal | - |
Ausbildung von Jennifer Michaelson
| Princeton University | Undergraduate Degree |
| Albert Einstein College of Medicine, Inc. | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| CULLINAN THERAPEUTICS, INC. | Health Technology |
| Private Unternehmen | 3 |
|---|---|
Jounce Therapeutics, Inc.
 Jounce Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Jounce Therapeutics, Inc. is a clinical stage immunotherapy company, which engages in developing treatments for cancer. It also provides novel cancer immunotherapies to attack tumors. The company was founded by Louis M. Weiner, Drew M. Pardoll, Thomas F. Gajewski, James P. Allison, Robert Schreiber, and Padmanee Sharma in 2013 and is headquartered in Cambridge, MA. | Commercial Services |
Cullinan Oncology LLC
Cullinan Oncology LLC Financial ConglomeratesFinance Cullinan Oncology LLC is a biopharmaceutical company, which engages in the development of a pipeline of targeted oncology and immuno-oncology therapies for cancer diseases. The company was founded by Patrick Baeuerle on September 15, 2016 and is headquartered in Cambridge, MA. | Finance |
Celsius Therapeutics, Inc.
Celsius Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Celsius Therapeutics, Inc. translates single-cell genomic insights into precision therapeutics for autoimmune diseases and cancer. The company was founded by Jeffrey A. Bluestone, Vijay K. Kuchroo, Christoph S. Lengauer, Aviv Regev and Ramnik Xavier in 2018 and is headquartered in Boston, MA. | Health Technology |
